Preserving Kidney Function Instead of Replacing It
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 4 of the 4 references it cites were found in a registry or an index.
Abstract
For the past 50 years, public and private funding priorities in the field of nephrology focused on kidney replacement therapy for ESKD: dialysis and transplantation. This focus was appropriate in a world where there were very few effective therapies to save lives or halt progressive loss of kidney function for the majority of CKDs. The time has come to change that paradigm as new strategies have emerged to prevent CKD progression and cardiovascular events in patients with CKD and diabetes. Until the latter half of the 20th century, the emerging discipline of nephrology examined the function of normal kidneys, the interaction of the kidneys with other vital organs, the kidneys’ role in multisystem dysfunction, and the physiology and pathophysiology of the many diseases affecting kidney function. In that era, physicians and scientists drawn to nephrology worked hard to preserve kidney function because there was no effective treatment for patients who developed irreversible kidney failure, and death was inevitable. Once it was shown that dialysis could remove uremic toxins and perform as an artificial kidney, attention turned to creating ways to preserve life once the kidneys failed. It was quickly shown that this technology could significantly extend the life of patients with ESKD and, in 1972, Congress passed the Social Security Amendments that provided Medicare coverage for virtually all Americans of any age who had ESKD (1). This public policy was the first and only to underwrite the care of a chronic disease for patients of any age. Currently, Medicare spends $35 billion annually for ESKD care (2). This public funding spawned the large dialysis industry and shaped the way we think about and treat kidney diseases. The prevalence of CKDs in the general population is approximately 15%. More than two thirds of those with CKDs or ESKD also have concurrent diabetes and/or cardiovascular disease (3). A system to classify the severity of CKDs was introduced in 2002. This helped quantify the burden of disease and anticipate ESKD, but a frequent unintended consequence was to focus on disease progression, rather than its underlying cause. In an era when research shed little light on treatments to ameliorate or stop progression of CKD to ESKD, public policy focused on treating kidney failure was appropriate. Although the mortality rate of CKD in diabetes is nearly 20% per year once kidney function begins to decline (4,5), research on ways to prevent CKD or slow its progression lagged behind similar research in other disciplines. Perhaps the wide availability of dialysis and underappreciation of the fatality risk contributed to the dearth of clinical studies. In other fields, where the risk of death and the unavailability of end stage disease treatment were apparent, a combination of activist pressure and federal government action accelerated research efforts that led to the rapid development of effective treatments. Perhaps the best example is the response to HIV/AIDS. During the first years of the AIDS epidemic, federal government responses were lackluster and conflicted. But eventually, largely due to the pressure of activists and a number of congressional supporters, legislation was passed to markedly enhance research into the etiology and treatment of AIDS and to underwrite the delivery of effective treatments to a largely marginalized AIDS population. Critical among these efforts was the expansion of AIDS research funding from <0.1% of the National Institutes of Health (NIH) budget in fiscal year 1982 to 9.8% of the NIH budget in fiscal year 1990 (6). In addition, the Health Resources and Services Administration’s Ryan White HIV/AIDS Program, enacted in 1990, provided “a comprehensive system of HIV primary medical care, essential support services, and medications for low-income people living with HIV who [were] uninsured and underserved. The Program funded grants to states, cities/counties, and local community-based organizations to provide care and treatment services to people living with HIV to improve health outcomes and reduce HIV transmission among hard-to-reach populations” (7). In addition, the Minority AIDS Initiative, passed in 1999 by Congress under the Ryan White Program, provided a new set of appropriations to improve access to HIV care and health outcomes for disproportionately affected minority populations, such as black people. As a result of all of these initiatives, by the end of the 1990s highly active antiretroviral therapy was widely disseminated and the number of new AIDS cases and deaths from HIV/AIDS plummeted. Importantly, federal funding for research, medical care, and community delivery of HIV/AIDS programs has continued now for >20 years. Fortunately, times are also changing for patients living with CKD. Recently published studies have shown clear evidence that new treatments for diabetes can slow or stop CKD progression and, importantly, reduce cardiovascular events, death, and the ne
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With new therapies that can reduce progression of CKD and diminish the burden of cardiovascular disease, including heart failure, it is time for those managing diabetes and CKD to focus on preserving kidney function and maintaining well-being rather than on replacing kidney function.37”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
Adler, A. I., Stevens, R. J., Manley, S. E., Bilous, R. W., Cull, C. A., Holman, R. R., & UKPDS Group (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00712.x · Cited by 1,816
Accepting Medication Therapy Management Recommendations to Add ACEIs or ARBs in Diabetes Care
Hurwitz, J. T., Grizzle, A. J., Augustine, J. M., Rehfeld, R. A., Wild, A., & Abraham, I. L. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.1.40 · Cited by 7
Cited by
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.013 · Cited by 274
Navaneethan, S. D., Zoungas, S., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Liew, A., Michos, E. D., Olowu, W. A., Sadusky, T., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2904 · Cited by 248
Preventing CKD in Developed Countries
Luyckx, V. A., Cherney, D. Z. I., & Bello, A. K. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2019.12.003 · Cited by 176
“Despite good evidence of their impact, uptake of renin–angiotensin– aldosterone system inhibitors early on was surprisingly slow.(115,137) Medications that inhibit the sodiumglucose cotransporter-2 (SGLT2) and glucagon-like peptide-1 receptor agonists (GLP1RAs) are emerging as important additional therapies for second…”
BackgroundMoving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease
Tuttle, K. R., Wong, L., St. Peter, W., Roberts, G., Rangaswami, J., Mottl, A., Kliger, A. S., Harris, R. C., Gee, P. O., Fowler, K., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02980322 · Cited by 87
Self-citationNephroprotection by SGLT2 Inhibition: Back to the Future?
Nicola, L. D., Gabbai, F. B., Garofalo, C., Conte, G., & Minutolo, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072243 · Cited by 47
Transforming the Care of Patients with Diabetic Kidney Disease
Brosius, F. C., Cherney, D. Z. I., Gee, P. O., Harris, R. C., Kliger, A. S., Tuttle, K. R., & Quaggin, S. E. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.18641120 · Cited by 28
Self-citationCan SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
Nicola, L. D., Cozzolino, M. G., Genovesi, S., Gesualdo, L., Grandaliano, G., & Pontremoli, R. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01336-7 · Cited by 17
Basutkar, R. S., Varghese, R., Mathew, N., Indira, P. S., Viswanathan, B., & Ponnusankar, S. (2021) · Nephrology · doi:10.1111/nep.14011 · Cited by 15
“Many novel strategies are emerging to preserve kidney function and to prevent progression of the disease.(4) In patients with CKD, phosphorus is retained because of hyperphosphatemia which leads to the development of ectopic calcification and secondary hyperparathyroidism.”
BackgroundRossing, P. R., Caramori, M. L., Chan, J. C. N., & Al., E. (2023) · KIDNEYS · doi:10.22141/2307-1257.11.4.2022.386 · Cited by 10
Combined Albuminuria and Estimated GFR Laboratory Reporting Affects Primary Care Management of CKD
Vassalotti, J. A., & Thavarajah, S. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2020.04.005 · Cited by 10
“protective therapies such as sodium-glucose cotransporter2 inhibitor and/or glucagon-like peptide 1 receptor agonists in type 2 diabetes.(19,20)”
BackgroundNicola, L. D., Ruotolo, C., Manna, G. L., Bellizzi, V., Gesualdo, L., Nappi, F., Ferraro, P. M., Marcantoni, C., Santoro, D., Stallone, G., et al. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106541 · Cited by 5
Rossing, P. R., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2481-2004 · Cited by 3
“…CKD ver-zögern und Belastungen durch Herz-Kreislauf-Erkrankungen, einschließlich Herzinsuffizienz, mindern, ist es an der Zeit, dass sich diejenigen, die Diabetes und CKD behandeln, auf den Erhalt der Nierenfunktion sowie des Wohlbefindens konzentrieren, anstatt die Nierenfunktion zu ersetzen [37].”
Tolvaptan or transplant: why wait?
Gordon, C. E., & Perrone, R. D. (2020) · Kidney International · doi:10.1016/j.kint.2020.03.022 · Cited by 3
Chronic kidney disease - a major public health problem
Groza, C., Groppa, L., Rotaru, L., Razlog, T., Popa, S., & Sasu, D. (2025) · Moldovan Journal of Health Sciences · doi:10.52645/mjhs.2025.2.09 · Cited by 8
Prescribing in paediatric kidney impairment
Dowsett, T., Awan, S., & McWilliam, S. J. (2021) · Archives of Disease in Childhood Education & Practice · doi:10.1136/archdischild-2021-322781 · Cited by 1
Can We Assess Interventions to Prevent Kidney Disease?
Vassalotti, J. A. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.01.014
Листратов, А. И., Ivanov, I. I., Ziskina, N. K., Efimenko, V. V., Zhavoronkova, A. V., Milyakova, E. S., Kudrjavtseva, A. A., Napalkov, D. A., & Sokolova, A. A. (2024) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2024-3066
New Therapies for the Management of Chronic Kidney Disease
Treihaft, A. M., Parikh, M. A., Jackson, K. A., Frishman, W. H., & Peterson, S. J. (2025) · Cureus · doi:10.7759/cureus.81824
Duni, Α., Tsavourelou, P., Triantafyllidou, M., Gkika, L., Georgopoulos, C., Stamellou, E., Κίτσος, Α., & Dounousi, E. C. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1759340 · Cited by 1
Management of Diabetic Kidney Disease
Ayyagari, U. (2025) · International journal of clinical metabolism and diabetes. · doi:10.1177/30502071261427510
“AGE, upon binding to receptors in various cells, and stimulation of toll-like receptors by hypergly-caemia trigger production of numerous cytokines (tumour necrosis factor [TNF], interleukin 6 [IL-6], IL-1beta) via activation of NF-κB and other nuclear transcription factors.”
Metadata
- Authors
- Kliger, A. S., Brosius, F. C., & on behalf of the Diabetic Kidney Disease Task Force of the American Society of Nephrology
- Affiliations
- American Society of Nephrology (US)
- University of Arizona (US)
- Corresponding author
- Kliger, Alan S.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2019-10-08
- Volume
- 15
- Issue
- 1
- Pages
- 129-131
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC6946074
- OpenAlex
- W2979593238
- Cited by
- 20
- References
- 4
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 1
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK114857)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- chronic kidney disease, end-stage renal disease, renal function preservation, renal replacement therapy, dialysis, kidney transplantation, chronic kidney disease progression, diabetes mellitus, cardiovascular risk, research funding priorities, history of nephrology, CKD risk stratification
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Angiotensin-Converting Enzyme Inhibitors, Renal Dialysis, Humans, Kidney, Renin-Angiotensin System, Kidney Transplantation, Treatment Outcome, Recovery of Function, Renal Insufficiency, Chronic, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.